Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage

Core Viewpoint - Voyager Therapeutics, Inc. (NASDAQ:VYGR) is recognized as a promising micro-cap stock by analysts, particularly following its strong Q3 performance and significant cash reserves [1][2]. Financial Performance - Voyager reported a loss per share of $0.47 for Q3 2025, which was $0.05 better than analyst expectations [3]. - The company's revenue for the quarter exceeded $13 million, representing a nearly 45% decline compared to the same period last year, but it surpassed market estimates by $5.5 million [3]. - Voyager ended the quarter with $229 million in cash, providing operational runway into 2028, and remains eligible for up to $2.4 billion in partner milestones [2]. Analyst Coverage - HC Wainwright has lowered the price target for Voyager from $30 to $25 while maintaining a Buy rating on the shares, reflecting confidence in the company's future despite the price adjustment [2]. Company Focus - Voyager Therapeutics is a biotechnology company that specializes in human genetics aimed at curing neurological diseases [4].